Skip NavigationSkip to Content

Design and Synthesis of Brefeldin a Sulfide Derivatives As Prodrug Candidates With Enhanced Aqueous Solubilities

  1. Author:
    Argade, A. B.
    Devraj, R.
    Vroman, J. A.
    Haugwitz, R. D.
    Hollingshead, M.
    Cushman, M.
  2. Author Address

    Cushman M, Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA NCI, Dev Therapeut Program, Div Canc Treatment & Diag, NIH, Rockville, MD 20852 USA NCI, Biol Testing Branch, Dev Therapeut Program, Div Canc Treatment & Diag, NIH, Fairview Ctr, Frederick, MD 21701 USA
    1. Year: 1998
  1. Journal: Journal of Medicinal Chemistry
    1. 41
    2. 18
    3. Pages: 3337-3346
  2. Type of Article: Article
  1. Abstract:

    The addition of a variety of thiols to the alpha,beta-unsaturated lactone functionality present in brefeldin A has been carried out, and the resulting sulfides have been oxidized to the corresponding sulfoxides. These sulfoxides have the potential to undergo syn elimination to regenerate brefeldin A. The sulfoxides were more active than the sulfides as cytotoxic agents in a variety of human cancer cell cultures with the activities of the sulfoxides approaching that of brefeldin A itself. The cytotoxicities of the sulfoxides may be due to their conversion back to brefeldin A. The kinetics of sulfoxide elimination to form brefeldin A were studied in four cases, and the results indicate that substantial amounts of brefeldin A are likely to be generated during the cytotoxicity assays of the sulfoxide derivatives. Since the oxidation of sulfides to sulfoxides is a common metabolic reaction, the sulfides derived from brefeldin A can be considered as potential brefeldin A prodrugs. Several of the sulfide derivatives were determined to have enhanced aqueous solubilities relative to brefeldin A itself, A number of brefeldin A succinates, glutarates, oxidation products, and sulfone derivatives were also prepared and evaluated for cytotoxicity in dancer cell cultures. Some of the more active brefeldin A derivatives were tested in an in vivo animal model in which hollow fibers containing cancer cell cultures were implanted subcutaneously (SC) and intraperitoneally (IF), and the compounds were administered IP. Greater cytotoxic activity was observed at the SC site than at the IP site for the majority of these compounds, an observation which is consistent with the hypothesis that they are acting as brefeldin A prodrugs in vivo. [References: 43]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel